Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alisertib with Weekly Paclitaxel in East Asian Patients with Advanced Solid Tumors
NCT02367352Phase 1Terminated
- Sponsor
- Millennium Pharmaceuticals
- Start
- Mar 2015
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of alisertib in solid tumor (advanced stage), ovarian cancer and small cell lung cancer (SCLC) (3 cohorts), sponsored by Millennium Pharmaceuticals. Primary endpoints: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs), Number of Participants With Clinically Significant Laboratory Findings and 8 more. Started Mar 2015; status: terminated.
02
Drugs
alisertib
03
Conditions
solid tumor (advanced stage)ovarian cancersmall cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT02367352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02367352.